Compare MRBK & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRBK | ACIU |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.4M | 213.3M |
| IPO Year | 2017 | 2016 |
| Metric | MRBK | ACIU |
|---|---|---|
| Price | $18.12 | $3.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $18.00 | $10.00 |
| AVG Volume (30 Days) | 81.4K | ★ 389.4K |
| Earning Date | 01-23-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ 75.95 | N/A |
| EPS | ★ 1.77 | N/A |
| Revenue | ★ $109,758,000.00 | $5,482,957.00 |
| Revenue This Year | $26.84 | N/A |
| Revenue Next Year | $8.90 | $644.42 |
| P/E Ratio | $10.27 | ★ N/A |
| Revenue Growth | ★ 18.84 | N/A |
| 52 Week Low | $11.16 | $1.43 |
| 52 Week High | $18.33 | $4.00 |
| Indicator | MRBK | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 67.54 | 55.11 |
| Support Level | $17.05 | $3.32 |
| Resistance Level | $17.91 | $3.80 |
| Average True Range (ATR) | 0.44 | 0.24 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 88.16 | 56.34 |
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.